Home Newsfeeds Gordon Haskett Downgrades Kohl’s to Hold, Announces $30 Price Target

Gordon Haskett Downgrades Kohl’s to Hold, Announces $30 Price Target

Gordon Haskett analyst Chuck Grom downgrades Kohl's (NYSE:KSS) from Accumulate to Hold and announces $30 price target.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Gordon Haskett analyst Chuck Grom downgrades Kohl’s (NYSE:KSS) from Accumulate to Hold and announces $30 price target.

After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy

By Vandana Singh

August 16, 7:43 AM

Everest Medicines will transfer all development and commercialization rights of Trodelvy (sacituzumab govitecan) to Gilead Sciences Inc (NASDAQ:GILD) in Greater China, South…

GILD

News

IMUNON Enters Into Technology Evaluation Agreement With Acuitas Therapeutics To Evaluate IMUNON’s PLACCINE Plasmid DNA With Acuitas’ Lipid Nanoparticle Delivery System

By Benzinga Newsdesk

November 10, 9:38 AM

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and Acuitas Therapeutics, a private biotechnology company focused on the development of delivery systems for nucleic acid vaccines and therapeutics

IMNN

Star Equity Holdings Q3 Adj EPS $0.05 Up From $(0.28) YoY, Sales $24.24M Miss $31.10M Estimate

By Benzinga Newsdesk

November 11, 9:31 AM

Star Equity Holdings (NASDAQ:STRR) reported quarterly earnings of $0.05 per share. This is a 117.86 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales

STRR

Markets
News

U.S. Bank: Freight Shipments And Costs Step Higher In Q2

By FreightWaves

July 20, 9:48 AM

Freight payments data released Wednesday showed a sequential uptick in trucking shipments during the second quarter, reversing the declining trend seen in the prior two quarters. Freight spending advanced again in the period as elevated fuel costs continue to push up all-in rates.

USB

Gordon Haskett Downgrades Kohl’s to Hold, Announces $30 Price Target

Related Posts

After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy

IMUNON Enters Into Technology Evaluation Agreement With Acuitas Therapeutics To Evaluate IMUNON’s PLACCINE Plasmid DNA With Acuitas’ Lipid Nanoparticle Delivery System

Star Equity Holdings Q3 Adj EPS $0.05 Up From $(0.28) YoY, Sales $24.24M Miss $31.10M Estimate

U.S. Bank: Freight Shipments And Costs Step Higher In Q2